{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:36:28Z","timestamp":1762659388934},"reference-count":11,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2014,10,28]],"date-time":"2014-10-28T00:00:00Z","timestamp":1414454400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Meda Pharma GmbH & Co. KG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2015,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Imiquimod 3.75% reduces 92.2% of all actinic keratosis (<jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content>) lesions, assumed to include both subclinical and clinical lesions, across a large sun\u2010exposed field such as the full face or balding scalp.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy of imiquimod 3.75% using the reduction in lesions from Lmax (the maximum lesion count during treatment) in subgroups of patients with low and high <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content> lesion counts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients from two 14\u2010week, placebo\u2010controlled, double\u2010blind studies were subgrouped according to whether they had \u226410 or &gt;10 <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content> lesions at baseline. Treatment was applied to the full face or balding scalp during two 2\u2010week treatment cycles separated by a 2\u2010week treatment\u2010free interval.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 167 patients had \u226410 lesions and 152 patients had &gt;10 <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content> lesions at baseline. With imiquimod 3.75%, the median percentage reduction in <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content> lesions from Lmax to end of study was similar in patients with \u226410 and &gt;10 baseline lesions (91.5% and 93.0% respectively). The median absolute reduction in <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content> lesions from Lmax to end of study was 24.0 for patients with &gt;10 baseline lesions and 10.0 for those with \u226410 baseline lesions. The median percentage and absolute reductions in lesions from Lmax were significantly greater with imiquimod 3.75% vs. placebo (<jats:italic>P<\/jats:italic>\u00a0&lt; 0.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Imiquimod 3.75% is effective regardless of disease severity as shown in this study by the reduction of over 90% of lesions from Lmax in patients with low or high <jats:styled-content style=\"fixed-case\">AK<\/jats:styled-content> lesion counts.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12782","type":"journal-article","created":{"date-parts":[[2014,10,29]],"date-time":"2014-10-29T03:23:53Z","timestamp":1414553033000},"page":"2470-2473","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of imiquimod 3.75% from Lmax according to the number of actinic keratosis lesions"],"prefix":"10.1111","volume":"29","author":[{"given":"K.","family":"Peris","sequence":"first","affiliation":[{"name":"Department of Dermatology Catholic University of Rome Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Stockfleth","sequence":"additional","affiliation":[{"name":"Department of Dermatology Charit\u00e9 \u2013 University Medical Centre Berlin Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Dermatology Monklands Hospital Airdrie Lanarkshire UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Aractingi","sequence":"additional","affiliation":[{"name":"Service de Dermatologie Allergologie H\u00f4pital Cochin Paris France"},{"name":"Universit\u00e9 Paris 5 Descartes Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Dakovic","sequence":"additional","affiliation":[{"name":"Meda Pharma GmbH &amp; Co. KG Bad Homburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Dirschka","sequence":"additional","affiliation":[{"name":"Dermatological Practice Centre Wuppertal Germany"},{"name":"Faculty of Health University Witten\u2010Herdecke Witten Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Alomar","sequence":"additional","affiliation":[{"name":"Department of Dermatology Institut Universitari Quiron Dexeus Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,10,28]]},"reference":[{"issue":"1","key":"e_1_2_6_2_1","first-page":"3","article-title":"Actinic keratosis and field cancerisation","volume":"21","author":"Stockfleth E","year":"2011","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_3_1","first-page":"651","article-title":"Development of a treatment algorithm for actinic keratoses: a European Consensus","volume":"18","author":"Stockfleth E","year":"2008","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_4_1","first-page":"43","article-title":"Actinic keratoses: a comprehensive update","volume":"2","author":"Ibrahim SF","year":"2009","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_6_5_1","first-page":"227","article-title":"Zyclara (imiquimod) cream, 3.75%","volume":"8","author":"Gupta AK","year":"2010","journal-title":"Skinmed"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.004"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000254893"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/135916"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1684\/ejd.2014.2265","article-title":"Reduction in lesions from Lmax: a new concept for assessing efficacy of field\u2010directed therapy for actinic keratosis. Results with imiquimod 3.75%","volume":"24","author":"Stockfleth E","year":"2014","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07942.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.01.047"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111170"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12782","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12782","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T08:05:41Z","timestamp":1695542741000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,28]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.1111\/jdv.12782"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12782","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,28]]}}}